Hyperlipidemia and cardiovascular disease after organ transplantation

Transplantation

Volumn 72, Issue 6 SUPPL., 2001, Pages

  Massy, Z A ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; AZATHIOPRINE; CHOLESTEROL; CORTICOSTEROID; CYCLOSPORIN; DEFLAZACORT; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; TRIACYLGLYCEROL;

ADULT; AGE; AGED; ALLOGRAFT; BODY WEIGHT; CARDIOVASCULAR DISEASE; CONFERENCE PAPER; DIET RESTRICTION; FEMALE; GRAFT SURVIVAL; HUMAN; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; LIPID BLOOD LEVEL; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; ORGAN TRANSPLANTATION; PATHOGENESIS; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0035959939     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200109271-00005     Document Type: Conference Paper

References (44)

1. 24th Bethesda Conference: Cardiac transplantation. Task Force 5: Complications
2. Lipid-lowering therapy in patients with renal disease
3. Hyperlipidemia in patients with chronic renal disease
4. Lack of left ventricular dysfunction associated with sustained exposure to hyperlipidemia following lung transplantation
5. Metabolic complications after liver transplantation
6. Prevalence of dyslipidemia in liver transplant recipients
7. Post-transplant hyperlipidemia: Mechanisms and management
8. Hyperlipidemia and post-heparin lipase activities in renal transplant recipients treated with sirolimus or cyclosporine A
9. Cardiovascular disease after renal transplantation
10. Carotid atheresclerosis in renal transplant recipients
11. Explained and unexplained ischemic heart disease risk after renal transplantation
12. Peripheral vascular disease in heart transplant recipients
13. Peripheral vascular involvement in heart transplant patients
14. Prospective evaluation of peripheral vascular disease in heart transplant recipients
15. Prominence of coronary arterial wall lipids in human heart allografts: Implications for pathogenesis of allograft arteriopathy
16. Pathology and etiology of chronic rejection of the heart
17. Apolipoproteins and immunohistological differentiation of cells in the arterial wall of kidneys in transplant arteriopathy: Morphological parallels with atherosclerosis
18. Peripheral vascular disease after kidney-pancreas transplantation in diabetic patients with end-stage renal disease
19. Cardiovascular complications following liver transplantation
20. Effect of pravastatin on outcomes after cardiac transplantation
21. Simvastatin reduces grace vessel disease and mortality after heart transplantation: A four-year randomized trial
22. Summary of the second report of the National Cholesterol Education Program (NCEP) (Adult Treatment Panel II)
23. Effect of alternate-day prednisone on plasma lipids in renal transplant recipients
24. Hyperlipidemia after renal transplantation in children on alternate day corticosteroid therapy
25. Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts
26. The effects of steroid withdrawal on the lipoprotein profiles of cyclosporine-treated kidney and kidney-pancreas transplant recipients
27. Late prednisone withdrawal in cyclosporine-treated kidney transplant patients: A randomized study
28. Hypercholesterolemia after heart transplantation: Amelioration by corticosteroid-free maintenance immunosuppression
29. Initial steroid-free versus steroid-based maintenance therapy and steroid withdrawal after heart transplantation: Two views of the steroid question
30. Randomised controlled trial of steroid withdrawal in renal transplant recipients receiving triple immunosuppression
31. Steroid-free immunosuppression after kidney transplantation with antithymocyte globulin induction and cyclosporine and mycophenolate mofetil maintenance therapy
32. Post-transplant conversion from cyclosporin to azathioprine: Effect on cardiovascular risk profile
33. Effects of deflazacort versus prednisone on bone mass, body composition, and lipid profile: A randomized, double blind study in kidney transplant patients
34. Mycophenolate mofetil in renal transplant recipients with cyclosporine-associated nephrotoxicity: A preliminary report
35. Effects of tacrolimus on hyperlipidemia after successful renal transplantation
36. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European other Societies on coronary prevention
37. Hyperlipidemia after heart transplantation: Report of a 6-year experience, with treatment recommendations
38. Lipid-lowering therapy and long-term survival in heart transplantation
39. Comparison of bezafibrate versus lovastatin for lowering plasma insulin, fibrinogen, and plasminogen activator inhibiter-1 concentrations in hyperlipemic heart transplant patients
40. Hyperlipidemia after liver transplantation
41. Pravastatin reduces serum cholesterol and low density lipoprotein concentrations following pancreas transplantation
42. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in transplant patients: Are the statins mechanistically similar?
43. Hyperlipidemia after renal transplantation: Treatment with gemfibrozil
44. Impact of time-interval after transplantation and therapy with fibrates on serum cholesterol levels in renal transplant patients